← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1 · 임상 갱신 필요 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV18행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 2
CABA-201 (CABA-201)
Cabaletta Bio·Pemphigus Vulgaris
6 trials
Overview
Program
CABA-201
Overview
Company
Cabaletta Bio
Overview
Modality
CGT
Overview
Target
Pemphigus Vulgaris
Overview
Indication
Relapsing Multiple Sclerosis (RMS); Progressive Multiple Sclerosis (PMS)
Overview
Phase
PHASE_2
Overview
Status
RECRUITING
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
PK/PD
Animal (cat.)
Unknown
PK/PD
Experiment
pd
Toxicology
Animal (cat.)
Unknown
Toxicology
Major finding
Non-targeted immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies.. Idiopathic inflammatory myopathies (IIM) are autoimmune-mediated inflammatory disorders of skeletal muscles with non-muscle involvement in some people, which carry significant morbidity and mortality. Treatment of IIM represents an area of unmet need. This review is an update of a review previous…
Toxicology
CRS
Reported
Clinical
Safety signal
Non-targeted immunosuppressive and immunomodulatory therapies for idiopathic inflammatory myopathies.. Idiopathic inflammatory myopathies (IIM) are autoimmune-mediated inflammatory disorders of skeletal muscles with non-muscle involvement in some people, which carry significant morbidity and mortality. Treatment of IIM represents an area of unmet need. This review is an update of a review previous…
Clinical
Program phase
PHASE_2